Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease.

ABSTRACT: Treatment strategies for inflammatory bowel disease (IBD) are rapidly evolving with the development of biologics and small molecule drugs (SMDs). However, these drugs are not guaranteed to be effective in all patients, and a "ceiling effect" of biologic monotherapy may occur. This issue highlights an unmet need for optimizing the use of biologics and predicting therapeutic responses. Thus, the development of new drugs with novel mechanisms of action is urgently needed for patients with primary nonresponse and secondary loss of response to conventional biologics and SMDs. In addition, combining different biologics or SMDs has been proposed as a novel strategy to enhance treatment efficacy in IBD, which theoretically has multidimensional anti-inflammatory potential. Based on the current evid

SUBMITTER: Xu YH 

PROVIDER: S-EPMC9827580 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature